The Global Nucleic Acid Isolation and Purification Market size is expected to reach $11.5 billion by 2030, rising at a market growth of 9.2% CAGR during the forecast period.
Circulating nucleic acid isolation and purification are crucial in liquid biopsy techniques, offering non-invasive methods for monitoring diseases, especially cancer. Therefore, the circulating nucleic acid isolation and purification segment captured $862.2 million revenue in the market in 2022. The ability to isolate and purify cfDNA or circRNA from blood samples allows for the detection and monitoring of tumor-related mutations, aiding in early diagnosis, treatment monitoring, and prognostic assessment.
The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, in October, 2023, Bio-Rad Laboratories, Inc. released two products, PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers, to enhance their product portfolio of PCR thermal cyclers. The new products help support PCR applications in process development and in basic and translational research. In September, 2023, Qiagen N.V introduced two products, the QIAwave RNeasy Plus Mini Kit and the QIAwave DNA/RNA Mini Kit, to enhance its QIAwave product portfolio. The new products are more sustainable than the standard kits from Qiagen and offer high-quality performance.
The leading players in the market are competing with diverse innovative offerings to remain competitive in the market. The above illustration shows the percentage of revenue shared by some of the leading companies in the market. The leading players of the market are adopting various strategies in order to cater demand coming from the different industries. The key developmental strategies in the market are Product Launches and Product Expansions.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Merck KGaA, Promega Corporation, Agilent Technologies, Inc., Danaher Corporation, Bio-Rad laboratories, Inc., Illumina, Inc., and New England Biolabs, Inc.
Circulating nucleic acid isolation and purification are crucial in liquid biopsy techniques, offering non-invasive methods for monitoring diseases, especially cancer. Therefore, the circulating nucleic acid isolation and purification segment captured $862.2 million revenue in the market in 2022. The ability to isolate and purify cfDNA or circRNA from blood samples allows for the detection and monitoring of tumor-related mutations, aiding in early diagnosis, treatment monitoring, and prognostic assessment.
The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, in October, 2023, Bio-Rad Laboratories, Inc. released two products, PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers, to enhance their product portfolio of PCR thermal cyclers. The new products help support PCR applications in process development and in basic and translational research. In September, 2023, Qiagen N.V introduced two products, the QIAwave RNeasy Plus Mini Kit and the QIAwave DNA/RNA Mini Kit, to enhance its QIAwave product portfolio. The new products are more sustainable than the standard kits from Qiagen and offer high-quality performance.
Cardinal Matrix - Market Competition Analysis
Based on the Analysis presented in the Cardinal matrix; F. Hoffmann-La Roche Ltd. is the forerunner in the market. In February, 2022, F. Hoffmann-La Roche Ltd. introduced the COVID-19 PCR tests like the cobas SARS-CoV-2 Qualitative and the cobas SARS-CoV-2 and Influenza A/B tests to the cobas 5800 System, a molecular laboratory instrument. The new products help to enhance the molecular product portfolio of Roche Diagnostics and offer better performance and strategies for the laboratory testing needs of all volumes. Companies such as Thermo Fisher Scientific, Inc., Danaher Corporation, Merck KGaA are some of the key innovators in market.Market Growth Factors
Increasing R&D in Genomics, Molecular Biology, and Personalized Medicine
Genomics involves the study of an organism's complete DNA sequence and how it functions. With the advent of high-throughput sequencing technologies (next-generation sequencing - NGS), there's been a massive surge in genomics research. These are essential steps in sequencing and analyzing the vast amounts of genetic data obtained, thus driving the need for efficient and reliable isolation and purification techniques. Furthermore, customized medicine entails adapting medical therapy to each patient's unique traits. This includes utilizing an individual's genetic information to select the most suitable treatment. Nucleic acid isolation and purification are fundamental steps in extracting and analyzing an individual's genetic material, enabling the development of targeted therapies, diagnostics, and treatment plans. These factors will drive the growth in the market.Ongoing Technological Improvements
Modern technologies have streamlined these processes, reducing manual intervention and human error. Automated systems, magnetic bead-based methods, and silica membrane-based purification have significantly improved efficiency, enabling higher throughput and faster processing of samples. Advanced methodologies, such as rapid kits and automated systems, have drastically reduced the time required for nucleic acid isolation and purification. Furthermore, the miniaturization of devices and the development of high-throughput platforms allow the simultaneous processing of multiple samples, significantly increasing the throughput capacity while maintaining quality and precision. Integrating nucleic acid isolation and purification techniques with other technologies, such as sequencing, PCR, microarray analysis, and CRISPR-based applications, has streamlined workflows, providing a seamless transition between various steps in these processes. These aspects will help accelerate the growth of the market.Market Restraining Factors
High Initial Investments
Smaller laboratories or research facilities with limited budgets may find it challenging to allocate a significant portion of their funds to purchase high-quality equipment. Due to budget constraints, some smaller laboratories may be unable to afford the latest and most efficient technologies. This can limit the quality and quantity of their research, potentially hampering their competitiveness and ability to secure research grants or collaborations. In addition to the initial investment, ongoing operational costs for consumables, maintenance, and skilled personnel can be substantial. Smaller labs with budget constraints may struggle to maintain these systems efficiently, leading to lower quality and throughput. Smaller laboratories may find it challenging to keep up with these innovations as they lack the resources to invest in new equipment and training. These factors will limit the growth in the market.The leading players in the market are competing with diverse innovative offerings to remain competitive in the market. The above illustration shows the percentage of revenue shared by some of the leading companies in the market. The leading players of the market are adopting various strategies in order to cater demand coming from the different industries. The key developmental strategies in the market are Product Launches and Product Expansions.
Application Outlook
Based on application, the market is divided into diagnostics, drug discovery & development, personalized medicine, agriculture & animal research, and others. The diagnostics segment recorded the maximum revenue share in the market in 2022. Molecular diagnostic tests, which rely on this, are increasingly being used for disease detection, monitoring, and treatment decisions. This includes applications in infectious disease testing, cancer diagnostics, genetic testing, and other areas. Ongoing technological advancements in these methods have made these processes more efficient, accurate, and faster.Product Outlook
Based on product, the market is segmented into kits, reagents, and instruments. In 2022, the instruments segment garnered a significant revenue share in the market. The demand for automated systems that can handle high sample volumes efficiently has significantly boosted the growth of instruments in this sector. These systems streamline this process, reducing human intervention and minimizing the chances of errors. Innovations in instrument design and functionality have played a crucial role in the market's growth.Method Outlook
On the basis of method, the market is divided into column based, magnetic beads, reagent based, and others. In 2022, the magnetic beads segment witnessed the maximum revenue share in the market. Magnetic bead-based isolation methods offer high efficiency in capturing nucleic acids from samples. These beads are functionalized with coatings that specifically bind nucleic acids, enabling highly selective extraction resulting in pure yields of DNA or RNA. The magnetic bead-based methods are highly amenable to automation and high-throughput processing, making them ideal for handling large volumes of samples simultaneously.Type Outlook
By type, the market is divided into plasmid DNA isolation & purification, total RNA isolation & purification, circulating nucleic acid isolation & purification, genomic DNA isolation & purification, messenger RNA isolation & purification, microRNA isolation & purification, and others. In 2022, the total RNA isolation and purification segment witnessed a promising revenue share in the market. The growing emphasis on understanding gene expression and regulation in molecular biology has driven the demand for high-quality RNA. Researchers require pure RNA samples for various applications, including gene expression studies, RNA sequencing, microarray analysis, and other molecular biology techniques. Thus, the segment will proliferate in the upcoming years.End User Outlook
On the basis of end user, the market is segmented into hospitals & diagnostic centres, academic research institutes, pharmaceutical & biotechnology companies, contract research organizations, and others. The hospitals and diagnostic centres segment held the largest revenue share in the market in 2022. Hospitals and diagnostic centres are increasingly incorporating molecular diagnostics into their services. This involves using these techniques to identify pathogens, genetic disorders, and various diseases. These facilities are adopting advanced technologies to provide accurate and quick diagnostic results.Regional Outlook
By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the market in 2022. North America is a hub for technological innovation in the life sciences and biotechnology sectors. Significant investments in research and development have led to the continuous evolution of these techniques. Advanced methods, automation, and high-throughput technologies are being developed and adopted, enhancing the efficiency and precision of these processes.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Merck KGaA, Promega Corporation, Agilent Technologies, Inc., Danaher Corporation, Bio-Rad laboratories, Inc., Illumina, Inc., and New England Biolabs, Inc.
Strategies deployed in the Market
Partnerships, Collaborations & Agreements:
- Jul-2023: Promega Corporation entered into an agreement with INOVIQ Limited, an Australian company in the biotechnology industry. Under this agreement, the companies marketed the EXO-NET exosome capture technology of INOVIQ and the Nucleic Acid purification systems of Promega globally. Additionally, the companies provided the customers with a wide range of products by incorporating the Promega manual and automated nucleic acid extraction reagents with the EXO-NET exosome capture tools of INOVIQ.
- Apr-2020: Thermo Fisher Scientific, Inc. formed a partnership with Hamilton Company, a manufacturer of automated liquid handling and sample management. Under this partnership, the ID NIMBUS Presto workstation was introduced. The ID NIMBUS Presto workstation helps in decreasing the time of sample preparation and offers high-quality nucleic acid purification.
- Jan-2020: F. Hoffmann-La Roche Ltd. came into an agreement with Illumina, Inc., an American biotechnology company. Under this agreement, the companies strengthened the worldwide adoption of NGS in cancer care. Additionally, Roche received the rights to develop the in-vitro diagnostic (IVD) tests on the NextSeq 550Dx System of Illumina.
Product Launches and Product Expansions:
- Oct-2023: Bio-Rad Laboratories, Inc. released two products, PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers, to enhance their product portfolio of PCR thermal cyclers. The new products help support PCR applications in process development and in basic and translational research. Additionally, the PTC Tempo Thermal Cyclers have the features of flexible connectivity and an intuitive user interface, which assist in regulating protocol management.
- Sep-2023: Qiagen N.V introduced two products, the QIAwave RNeasy Plus Mini Kit and the QIAwave DNA/RNA Mini Kit, to enhance its QIAwave product portfolio. The new products are more sustainable than the standard kits from Qiagen and offer high-quality performance. Additionally, the new product increases the eco-friendly product options of the company and provides scientific advancement without causing environmental degradation.
- Jan-2023: Qiagen N.V launched the EZ2 Connect MDx, which can be used in laboratories. The EZ2 Connect MDx performs the purification of DNA and RNA from 24 samples simultaneously over a time period of 30 minutes.
- Feb-2022: F. Hoffmann-La Roche Ltd. introduced the COVID-19 PCR tests like the cobas SARS-CoV-2 Qualitative and the cobas SARS-CoV-2 and Influenza A/B tests to the cobas 5800 System, a molecular laboratory instrument. The new products help to enhance the molecular product portfolio of Roche Diagnostics and offer better performance and strategies for the laboratory testing needs of all volumes. Additionally, the new product assists healthcare systems with limited spaces and resources.
- Dec-2021: F. Hoffmann-La Roche Ltd. introduced infectious disease tests like cobas HIV-1, cobas HCV, cobas HBV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni–Utility Channel kit to the cobas 5800 System, which is a molecular laboratory instrument. The new products help to enhance the molecular product portfolio of Roche by providing organized efficiencies and performances for molecular laboratory requirements of various volumes.
- Oct-2021: Thermo Fisher Scientific, Inc. unveiled the MagMAX Wastewater Ultra Nucleic Acid Isolation Kit, a testing method to determine infection rates about two weeks earlier than other pooled and individual testing. The MagMAX Wastewater Ultra Nucleic Acid Isolation Kit offers solutions for conveniently implementing surveillance programs and installing SARS-CoV-2 testing methods in both existing and newly constructed labs.
- Mar-2021: Promega Corporation launched the XpressAmp Direct Amplification Reagents, which enable automated sample preparation through a method without the involvement of RNA extraction. The XpressAmp Direct Amplification Reagents assist COVID-19 testing laboratories to eliminate the RNA extraction procedures and directly shift to conducting the polymerase chain reaction (PCR).
Acquisition and Mergers:
- Jan-2023: Qiagen N.V. took over Verogen, Inc., a developer of DNA-based biometric human identification products for analysis of forensic genomic samples. Through this acquisition, both companies provided unique solutions to improve investigations and research to advance forensic science, find missing persons, and identify suspects accurately.
- May-2022: Qiagen N.V completed the acquisition of BLIRT S.A., a European manufacturer of recombinant enzymes for the life science industry. Through this acquisition, Qiagen enhanced its capabilities and strengthened its reagents and enzyme businesses.
- Apr-2020: Bio-Rad Laboratories, Inc. took over Celsee, Inc., a company offering instruments for analyzing single cells. Through this acquisition, Bio-Rad Laboratories utilized the Genesis System of Celsee to gather cell-based information and interpret cellular behaviour to get better results. Additionally, the acquisition helped to monitor tumor cell circulation and find out the disease progression and the required therapeutic response.
Scope of the Study
Market Segments Covered in the Report:
By Application- Diagnostics
- Drug Discovery & Development
- Agriculture & Animal Research
- Personalized Medicine & Others
- Reagents
- Kits
- Instruments
- Magnetic Beads
- Column Based
- Reagent Based
- Others
- Plasmid DNA Isolation & Purification
- Total RNA Isolation & Purification
- Circulating Nucleic Acid Isolation & Purification
- Genomic DNA Isolation & Purification
- Messenger RNA Isolation & Purification
- microRNA Isolation & Purification
- Others
- Hospitals & Diagnostic Centers
- Pharmaceutical & Biotechnology Companies
- Academic Research Institutes
- Contract Research Organizations
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc.
- Qiagen N.V.
- F.Hoffmann-La Roche Ltd.
- Merck KGaA
- Promega Corporation
- Agilent Technologies, Inc.
- Danaher Corporation
- Bio-Rad laboratories, Inc.
- Illumina, Inc.
- New England Biolabs, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Global Nucleic Acid Isolation and Purification Market by Application
Chapter 6. Global Nucleic Acid Isolation and Purification Market by Product
Chapter 7. Global Nucleic Acid Isolation and Purification Market by Method
Chapter 8. Global Nucleic Acid Isolation and Purification Market by Type
Chapter 9. Global Nucleic Acid Isolation and Purification Market by End User
Chapter 10. Global Nucleic Acid Isolation and Purification Market by Region
Chapter 11. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Qiagen N.V.
- F. Hoffmann-La Roche Ltd.
- Merck KGaA
- Promega Corporation
- Agilent Technologies, Inc.
- Danaher Corporation
- Bio-Rad laboratories, Inc.
- Illumina, Inc.
- New England Biolabs, Inc.
Methodology
LOADING...
